Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: Reduction of interassay variability

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 3, 2011, Pages 267-271

  Harenberg, Job ^a   Krämer, Roland ^a   Giese, Christina ^a   Marx, Svetlana ^a   Weiss, Christel ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticoagulants; Chromogenic assay; Factor Xa; Oral direct factor Xa inhibitors; Rivaroxaban

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; RIVAROXABAN;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DYE DILUTION CURVE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; HUMAN; INTERMETHOD COMPARISON; MOLECULAR WEIGHT; OPTICAL DENSITY; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; VALIDATION PROCESS;

ANTICOAGULANTS; CHROMOGENIC COMPOUNDS; FACTOR XA; HUMANS; MORPHOLINES; THIOPHENES;

EID: 82955195864     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0622-5     Document Type: Article

References (18)

1. Weitz JI (2010) New oral anticoagulants in development. Thromb Haemost 103:62-70
2. Bounameaux H, Reber G (2010) New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 8:627-630
3. Favaloro EJ, Lippi G (2011) Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med 49:755-757
4. Mismetti P, Laporte S (2010) New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 8:621-626
5. Mueck W, Becka M, Kubitza D et al (2007) Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 45:335-344 (Pubitemid 46895052)
6. Misselwitz F, Berkowitz SD, Perzborn E (2011) The discovery and development of rivaroxaban. Ann N Y Acad Sci 1222:64-75
7. Eriksson BI, Borris L, Dahl OE et al (2006) Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121-128
8. Turpie AG, Fisher WD, Bauer KA et al (2005) BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3:2479-2486 (Pubitemid 41727165)
9. Samama MM, Martinoli JL, LeFlem L, Guinet C et al (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 103:815-825
10. Tripodi A, Chantarangkul V, Guinet C, Samama M (2011) The INR calibrated for rivaroxaban-(INRrivaroxaban) has the potential to normalize PT results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9:226-228
11. Barrett YC, Wang Z, Frost C, Shenker A (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:1263-1271
12. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P et al (2005) Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin- 4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900-5908 (Pubitemid 41324601)
13. Harenberg J, Marx S, Krämer R, Giese C, Weiss C (2011) Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinol. (In press)
14. Harenberg J (2011) Report of the working party on standardization of methods to determine direct factor Xa inhibitors http://ssc2010.org/ssc2010/ index.cfm/program/ssc-sessions/Monday-24-may/Assessed 28 June, 2011
15. McGlasson DL, Kaczor DA, Krasuski RA et al (2005) Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagul Fibrinolysis 16:173-176 (Pubitemid 40547270)
16. van Geest-Daalderop JH, Hutten BA, Péquériaux NC et al (2007) The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose. Thromb Haemost 4:738-746 (Pubitemid 47555064)
17. Gerotziafas GT, Dupont C, Spyropoulos AC et al (2009) Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low molecular-eight heparin. Thromb Haemost 102:42-4818
18. Perzborn E, Harwardt M, Samama MM (2009) Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor, ISTH. J Thromb Haemost 7(Suppl 2) (Abstract PP-MO-185)